A Phase 3 interventional study of Itepekimab (SAR440340) and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Completed at 223 sites in 32 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-18.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 3, and was the 8th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 40+
Sanofi · Sites in France
Ages 18+
Sanofi · Sites in United States, Argentina, Austria and 19 more countries
Ages 40–85
Sanofi · Sites in United States, Argentina, Australia and 23 more countries
Ages 40–80
Sanofi · Sites in United States, Argentina, Belgium and 22 more countries
Ages 40–80
By country, each count listing its studies:
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2024.
This study's enrollment of 669 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 937 across the 12 interventional studies, 350 across the 3 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.
The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819.
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Patients with who completed the treatment period in a previous itepekimab COPD Phase 3 clinical study (ie, EFC16750 or EFC16819) and for which an end-of-treatment (EOT) visit occurred no later than 3 days before the enrolment visit of this study.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
Drug: Itepekimab (SAR440340)
SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
Drug: Itepekimab (SAR440340) · Drug: Placebo
Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
Also known as: REGN3500
Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
Incidence of treatment-emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation
All AEs (serious or nonserious) will be collected from the signing of the informed consent form (ICF) until the end of study visit
Time frame: Baseline up to Week 72
Functional itepekimab concentrations in serum
Time frame: Baseline up to Week 52
Incidence of treatment-emergent (TE) anti-drug antibody responses
Time frame: Baseline up to Week 72
Annualized rate of moderate-to-severe acute exacerbation of COPD (AECOPD)
Time frame: Baseline up to Week 52
Annualized rate of severe AECOPD
Time frame: Baseline up to Week 52
Time to first moderate-to-severe AECOPD
Time frame: Baseline up to Week 52
Time to first severe AECOPD
Time frame: Baseline up to Week 52
Change from baseline of the parent studies (EFC16750, EFC16819): Pre-BD and post-BD FEV1
FEV1 is force expiratory volume in 1 second
Time frame: Baseline of the parent studies (EFC16750,EFC16819) up to Week 52
Change from baseline of the parent studies (EFC16750, EFC16819): SGRQ total score and domain scores
The St. George's Respiratory Questionnaire (SGRQ) is a 50-item questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation.
Time frame: Baseline of the parent studies (EFC16750,EFC16819) up to Week 52
Change from baseline of the parent studies (EFC16750, EFC16819): EQ-5D-5L single index score
The European Quality of Life 5 Dimensions 5 Level Version (EQ 5D 5L) is a standardized health-related quality-of-life (HRQoL) questionnaire which consists of a descriptive system and the EuroQol visual analog scale (EQ-VAS).
Time frame: Baseline of the parent studies (EFC16750,EFC16819) up to Week 52
Change from baseline of the parent studies (EFC16750, EFC16819): EQ-VAS
The EuroQol visual analog scale (EQ VAS) records the participant's self-rated health on a vertical VAS.
Time frame: Baseline of the parent studies (EFC16750,EFC16819) up to Week 52
Change from Week 0 for CASA-Q
The cough and sputum assessment questionnaire (CASA-Q) was developed for use in COPD and chronic (non-obstructive) bronchitis patients.
Time frame: Baseline up to Week 52
Showing the first 100 of 223 sites across 32 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Sep 2026, 31 months.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 31 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itepekimab
Pulmonary Disease, Chronic Obstructive →